Baseline concentrations of fasting and post-load glycaemic variables, i.e., glucose, insulin, proinsulin and C-peptide, did not differ between the two groups, while mannose levels were slightly higher in the empagliflozin group compared to placebo (92.7 vs. 86.1 μmol/L, p = 0.04; Supplemental Table 2) and were significantly higher in patients with T2DM than those with IGT (86.1 vs. 76.1 μmol/L, p = 0.02). This evidence concerns the gene INS and type 2 diabetes mellitus.